Created at	Source	Raw Value	Validated value
June 16, 2023, 8 a.m.	usa	Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes Post-vaccination to Either Dose of Pfizer-BioNTech COVID-19 Vaccine.;Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes Post-vaccination to Either Dose of the Moderna COVID-19 Vaccine.	Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes Post-vaccination to Either Dose of Pfizer-BioNTech COVID-19 Vaccine.;Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes Post-vaccination to Either Dose of the Moderna COVID-19 Vaccine.
Feb. 23, 2021, 12:31 a.m.	usa	Proportion of participants who experience a systemic allergic reaction to either dose of the Moderna COVID-19 Vaccine;Proportion of participants who experience a systemic allergic reaction to either dose of the Pfizer-BioNTech COVID-19 Vaccine	Proportion of participants who experience a systemic allergic reaction to either dose of the Moderna COVID-19 Vaccine;Proportion of participants who experience a systemic allergic reaction to either dose of the Pfizer-BioNTech COVID-19 Vaccine